Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **phosphatidylinositol 3‑kinase–Akt–mammalian target of rapamycin–ribosomal protein S6 kinase beta‑1** (**PI3K‑Akt‑mTOR‑S6K1**) **signaling pathway** is a highly conserved intracellular signal transduction cascade that regulates critical cellular processes including growth, survival, metabolism, proliferation, differentiation, and apoptosis. Activation typically begins at the cell surface via growth factor receptors that stimulate phosphatidylinositol 3‑kinase (**PI3K**), leading to production of phosphoinositide second messengers that recruit **Akt** (**protein kinase B**) to the plasma membrane for activation. Activated Akt phosphorylates numerous substrates involved in promoting survival and growth while inhibiting apoptosis. One major downstream effector is **mammalian/mechanistic target of rapamycin** (**mTOR**), which integrates nutrient sensing with mitogenic signals to regulate translation through phosphorylation/activation of targets like **S6 kinase beta‑1** (**S6K1**, also known as p70S6 kinase). Dysregulation—often via mutation or loss-of-function in negative regulators like PTEN—leads to constitutive activity associated with oncogenesis across many tumor types including breast cancer and acute myeloid leukemia.[1][2][8] The complexity arises because this "target" refers not to one molecule but an entire networked axis comprising multiple druggable nodes. This entry does not correspond to a single molecular entity but rather describes an integrated network/pathway composed primarily of enzymes/kinases; thus it should not be considered a canonical therapeutic "target" per se but rather a collection/set thereof.[2][9]
Drugs act by inhibiting specific kinases within the pathway to block downstream pro-survival and proliferative signals. For example: - Inhibition of mTOR blocks protein synthesis and cell growth. - Inhibition of PI3K prevents activation of Akt and downstream effectors.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin–ribosomal protein S6 kinase beta-1 signaling pathway (PI3K-Akt-mTOR-S6K1 signaling pathway).